Mental Health Monitoring
Watching mood during weight treatment — labels advise monitoring for depression and suicidal thoughts, and support exists.
Weight-management drug labels have long advised monitoring for new or worsening depression and suicidal ideation — a legacy of older drugs with clear psychiatric effects, carried forward cautiously. For GLP-1 therapy specifically, large reviews including FDA and European analyses have not established a causal link, but the monitoring language stands and the stakes justify it.
The operational version: know your baseline, tell your prescriber about psychiatric history (it's screening-relevant, not disqualifying by default), and treat persistent mood change, hopelessness, or intrusive thoughts during treatment as reportable symptoms — to your prescriber, and in crisis to 988 (call or text, U.S.). Weight loss also reshuffles identity, habits, and even how alcohol lands; naming those shifts early keeps them manageable.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about Mental Health Monitoring? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment